KaydedilenlerDerginizi ekleyin

Dergiler / Annals of Medical Research / 2022 / Cilt: 29 - Sayı: 2

Downregulation of CD44 regulates extracellular matrix degradation in human pancreatic ductal adenocarcinoma cells

Nilgün GÜRBÜZ
Furkan İlker ÖZBALCI
Sayfa
87–92
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

CD44 is also promising target for against PDAC through inhibiting migration, invasion and metastasis steps.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: Pancreatic ductal adenocarcinoma (PDAC) has high mortality and early stage metastatic potential.
📊
Temel Bulgular & Veri:Thus, the developing new clinical approach and metastasis blocking strategy-based drugs are essential for cure of PDAC.
💡
Sonuç & Katkı:CD44 is also promising target for against PDAC through inhibiting migration, invasion and metastasis steps.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Aim: Pancreatic ductal adenocarcinoma (PDAC) has high mortality and early stage metastatic potential. Thus, the developing new clinical approach and metastasis blocking strategy-based drugs are essential for cure of PDAC. In this study we aimed to investigate the effects of cell surface transmembrane glycoprotein CD44 on the regulation of key ECM proteins, integrin β1, fibronectin and collagen IV, in Panc-1 and MiaPaCa-2 cells. Materials and Methods: Followed by cell viability assay using MTS, fibronectin and collagen IV protein expression levels and integrin β1 mRNA level were analyzed in Panc-1 and MiaPaCa-2 cells treated with 50 nM negative siRNA and CD44 siRNA for 72 h using western blot and RT-PCR, respectively. Results: Based on our findings, the downregulation of CD44 using specific siRNA led to decrease fibronectin and collagen IV proteins expressions, and also Integrin β1 mRNA expression in both Panc-1 and MiaPaCa-2 cell lines. Conclusion: CD44 siRNA based therapies have effective role to inhibit ECM degradation in PDAC progression. CD44 is also promising target for against PDAC through inhibiting migration, invasion and metastasis steps.

🔖

Bu Makaleye Atıf Yap

GÜRBÜZ, N., ÖZBALCI, F. İ. (2022). Downregulation of CD44 regulates extracellular matrix degradation in human pancreatic ductal adenocarcinoma cells. Annals of Medical Research, Cilt: 29 - Sayı: 2, 87–92. https://ajindex.com/articles/445660

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (16)

  1. Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr JM, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. Pancreatology 2015;15:8–18
  2. Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol (Madr) 2016;55:1158–60
  3. Rebelatto TF, Falavigna M, Pozzari M, Spada F, Cella CA, Laffi A, et al. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. Cancer Treat Rev 2019;80:101895
  4. Mouw JK, Ou G, Weaver VM. Extracellular matrix assembly: A multiscale deconstruction. Nat Rev Mol Cell Biol 2014;15:771–85
  5. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep 2014;15:1243–53
  6. Erkan M, Reiser-Erkan C, Michalski CW, Kleeff J. Tumor microenvironment and progression of pancreatic cancer. Exp Oncol 2010;32:128–31
  7. Sato N, Cheng XB, Kohi S, Koga A, Hirata K. Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma. Acta Pharm Sin B 2016;6:101–5
  8. Senbanjo LT, Chellaiah MA. CD44: A multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front Cell Dev Biol 2017;5:18
  9. Chen L, Fu C, Zhang Q, He C, Zhang F, Wei Q. The role of CD44 in pathological angiogenesis. FASEB J 2020;34:13125–39
  10. Xu H, Niu M, Yuan X, Wu K, Liu A. CD44 as a tumor biomarker and therapeutic target. Exp Hematol Oncol 2020;9:36
  11. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 2010;46:1271–7
  12. Gurbuz N, Ashour AA, Alpay SN, Ozpolat B. Down-regulation of 5-HT1B and 5-HT1D receptors inhibits proliferation, clonogenicity and invasion of human pancreatic cancer cells. PLoS One 2014;9:e110067
  13. Sun Q., Zhou C., Ma R., Guo Q., Huang H., Hao J., Liu B. (2018). Prognostic value of increased integrin-beta 1 expression in solid cancers: a meta- analysis. OncoTargets and therapy, 11, 1787
  14. Bulle A., Lim K. H. (2020). Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal Transduction and Targeted Therapy, 2020;5:1-12
  15. Takada Y, Ye X, Simon S. The integrins. Genome Biol 2007;8:1–9
  16. Das M, Subbayya Ithychanda S, Qin J, Plow EF. Mechanisms of talindependent integrin signaling and crosstalk. Biochim Biophys Ac